Work spearheaded by Aram Ghalali and led by Michael Rogers and Bruce Zetter at Harvard Medical School, Boston, USA, explored the consequences of AZIN1 RNA editing in prostate cancer. This evidence concerns the gene AZIN1 and prostate carcinoma.